Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
Standard antipsychotic drug regimens do not fully address the impact of cognitive symptoms
associated with schizophrenia. The NMDA receptor has been connected to the pathophysiology of
schizophrenia. Memantine is an uncompetitive NMDA receptor antagonist. It is hypothesized
that adjunctive therapy with memantine will reduce NMDA receptor hyperactivity, improving
signal to noise ratio and thereby improving cognitive symptoms.